A biometric method includes: a step (1) for administering, to a target organism from the outside thereof, one of (i) a target molecule A having both an unpaired electron and a magnetic resonance nucleus having a gyromagnetic ratio smaller than the same of .sup.19F, and (ii) a target molecule B and a radical molecule C, the target molecule B having no unpaired electron, and further having a magnetic resonance nucleus having a gyromagnetic ratio smaller than the same of .sup.19F, the radical molecule C having an unpaired electron; and a step (2) for causing electron spin resonance in the unpaired electron of the target molecule A or the radical molecule C by irradiating electromagnetic waves to the target organism, subsequently triggering nuclear magnetic resonance in the magnetic resonance nucleus having a gyromagnetic ratio smaller than the same of .sup.19F in one of the target molecule A and the target molecule B, and further, measuring nuclear magnetic resonance signals. The step (2) is carried out in a magnetic field having such an intensity that the nuclear magnetic resonance signals of the magnetic resonance nucleus in one of the target molecule A and the target molecule B are degenerated, the magnetic resonance nucleus having a gyromagnetic ratio smaller than the same of .sup.19F. The biometric method makes it possible to measure low-sensitivity magnetic resonance nucleus such as .sup.13C, .sup.15N, and .sup.31P, which are important nuclides present in organism, with performance equal to or over that of a high-field MRI device.

The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds.

The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds.

A fluorine-containing compound represented by Formula (1) or Formula (2) (R.sup.1, R.sup.2, and R.sup.3 in Formula (1) and R.sup.4 and R.sup.5 in Formula (2) each represent a C1-10 alkyl group unsubstituted or substituted with a substituent containing no fluorine atoms, and X.sup.1 in Formula (1) and X.sup.2 and X.sup.3 in Formula (2) are any of Formulae (3-1) to (3-4).)

##STR00001##

The present invention relates to nitroxide imaging probes that are isotopically modified or unmodified. Such nitroxide imaging probes may be included in liposomes that encapsulate self-quenching concentrations thereof, wherein the liposomes optionally comprise a targeting ligand specific to and having affinity for targeted tissue.

The present invention relates to nitroxide imaging probes that are isotopically modified or unmodified. Such nitroxide imaging probes may be included in liposomes that encapsulate self-quenching concentrations thereof, wherein the liposomes optionally comprise a targeting ligand specific to and having affinity for targeted tissue.

Disclosed are methods, compositions, reagents, systems, and kits to prepare nitroxide-functionalized brush-arm star polymer organic radical contrast agent (BASP-ORCA) as well as compositions and uses thereof. Various embodiments show that BASP-ORCA display unprecedented per-nitroxide and per-molecule transverse relaxivities for organic radical contrast agents, exceptional stability, high water solubility, low in vitro and in vivo toxicity, and long blood compartment half-life. These materials have the potential to be adopted for tumor imaging using clinical high-field .sup.1H MRI techniques.

The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds.

The present invention provides methods of using nitroxide spin-labeled amyloid beta-binding compounds to image amyloid. The present invention also provides nitroxide spin-labeled amyloid beta-binding compounds.

A method of imaging a joint of a subject comprises administering to the subject an amount of a salt of DAB-4 linked nitroxide citrate effective to enhance an MRI image of the joint and taking an MRI image of said joint.